BEIJING, China, June 12, 2026
Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) has announced a significant step forward in its international medical technology strategy by advancing the compliance work and regulatory procedures required for U.S. FDA establishment registration and device listing of one of its innovative acoustic brain-computer interface (BCI) products. The development marks an important milestone in the company’s efforts to expand its presence in the global healthcare technology market while strengthening its portfolio of acoustic medical and AI-powered health solutions. The company confirmed that it has submitted its Dun & Bradstreet Data Universal Numbering System (DUNS) application, a foundational administrative requirement supporting future FDA-related registration activities. While the product has not yet received FDA clearance or approval for commercial distribution in the United States, the latest progress demonstrates Datasea’s commitment to preparing for future regulatory pathways and international commercialization opportunities.
Acoustic Brain-Computer Interface Targets Emerging Healthcare Applications
Datasea’s acoustic BCI product is built upon the company’s expanding acoustic medical technology roadmap, integrating four core technologies including acoustic stimulation, bone-conduction neuromodulation, EEG signal acquisition, and AI-assisted health management. The platform is designed to support a variety of non-invasive neurological and wellness-related applications, including brain health management, rehabilitation support, cognitive function monitoring, sleep quality optimization, and emotional regulation. Unlike traditional invasive brain-computer interface systems, Datasea’s approach focuses on combining acoustic intervention with physiological monitoring and artificial intelligence analysis.
According to the company, this differentiated strategy may offer advantages related to safety, accessibility, user compliance, and long-term commercialization potential. As interest in non-invasive neurotechnology continues to grow, acoustic neuromodulation is emerging as a promising area within the broader digital health and medical device sectors.
FDA Registration Preparations Strengthen Global Expansion Strategy
Advertisement
The company emphasized that the advancement of FDA-related preparatory activities forms a key component of its broader international expansion strategy. Datasea plans to continue a systematic compliance process that includes establishment registration preparation, device listing documentation, technical file development, product testing, regulatory communications, and additional supporting procedures. Company leadership stated that these efforts are intended to strengthen the competitiveness of its future medical technology portfolio while supporting entry into international markets.
Chief Executive Officer Zhixin Liu noted that Datasea continues to expand its acoustic intelligence businesses across healthcare, wellness, and AI-powered applications, positioning acoustic neuromodulation and brain-computer interface technologies as important long-term growth opportunities. The company believes that ongoing investments in research, product development, and regulatory readiness will help establish stronger technological barriers and create future value within the rapidly evolving neurotechnology sector.
Regulatory Milestone Highlights Growing MedTech Ambitions
Although Datasea clarified that the DUNS application, establishment registration process, and device listing activities do not constitute FDA approval, clearance, or authorization for commercial distribution, the announcement reflects meaningful progress toward regulatory preparedness. The company acknowledged that future FDA-related procedures remain subject to review timelines, regulatory requirements, and potential outcomes. Nevertheless, the initiative underscores the increasing importance of regulatory compliance in the commercialization of advanced medical technologies.
With healthcare organizations and investors paying closer attention to innovations in brain-computer interfaces, AI-driven health management, and non-invasive neuromodulation, Datasea’s latest move signals growing momentum in the convergence of neuroscience, digital health, and medical device innovation. As the company advances its acoustic medical portfolio, industry stakeholders will be closely watching future developments related to regulatory filings, clinical validation, and commercialization opportunities in the United States and other global markets.
Source: Datasea Intelligent Technology press release
